A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422)

A. Jatoi, S. E. Schild, N. Foster, G. T. Henning, K. J. Dornfeld, P. J. Flynn, T. R. Fitch, S. R. Dakhil, K. M. Rowland, P. J. Stella, G. S. Soori, A. A. Adjei

Research output: Contribution to journalArticlepeer-review

42 Scopus citations

Abstract

Background: Non-small-cell lung cancer (NSCLC) is a disease of the elderly. Seeking a tolerable but effective regimen, we tested cetuximab + radiation in elderly and/or poor performance status patients with locally advanced NSCLC. Patients and methods: Older patients [≥65 years with an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2] or younger patients (performance status of 2) received cetuximab 400 mg/m2 i.v. on day 1 followed by weekly cetuximab 250 mg/m2 i.v. with concomitant radiation of 6000 cGy in 30 fractions. The primary end point was the percentage who lived 11+ months.Results: This 57-patient cohort had a median age (range) of 77 years (60-87), and 12 (21%) had a performance status of 2. Forty of 57 (70%) lived 11+ months, thus exceeding the anticipated survival rate of 50%. The median survival was 15.1 months [95% confidence interval (CI) 13.1-19.3 months], and the median time to cancer progression was 7.2 months (95% CI 5.8-8.6 months). No treatment-related deaths occurred, but 31 patients experienced grade 3+ adverse events, most commonly fatigue, anorexia, dyspnea, rash, and dysphagia, each of which occurred in <10% of patients.Conclusion: This combination merits further study in this group of patients.

Original languageEnglish (US)
Pages (from-to)2040-2044
Number of pages5
JournalAnnals of Oncology
Volume21
Issue number10
DOIs
StatePublished - Jun 21 2010

Keywords

  • Cetuximab
  • Elderly
  • Lung cancer
  • Poor performance status
  • Radiation

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422)'. Together they form a unique fingerprint.

Cite this